{"id":26035,"date":"2023-12-13T18:05:38","date_gmt":"2023-12-13T12:35:38","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=26035"},"modified":"2024-09-17T17:01:20","modified_gmt":"2024-09-17T11:31:20","slug":"final-analysis-of-the-phase-2-elm-2-study","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/final-analysis-of-the-phase-2-elm-2-study","title":{"rendered":"Odronextamab Trial: Striking Response Rates and Enduring Outcomes in High-Risk R\/R DLBCL Subgroups"},"content":{"rendered":"\n
Date of Abstract presentation<\/td>10th December 2023<\/td><\/tr>
Indications<\/td>Diffuse Large B-cell lymphoma (DLBCL)<\/td><\/tr>
Abstract Number<\/td>436<\/td><\/tr>
Abstract type<\/td>Oral<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Odronextamab is an investigational CD20xCD3 bispecific antibody designed to bridge CD20 on cancer cells with CD3-expressing T cells to facilitate local T-cell activation and cancer-cell killing. The primary analysis of the Phase II trial presented at the ASH 2023 demonstrated that, among 127 DLBCL patients treated with odronextamab, the reported objective response rate (ORR) was 52%, with 31% achieving a complete response (CR). <\/strong>Moreover, <\/strong>the <\/strong>responses were observed across high-risk subgroups, including those with International Prognosis Index (IPI) high-risk scores of 3 to 5, high-grade lymphoma that is double-hit and triple-hit, and transformed DLBCL. Furthermore, the median duration of response (DoR) was 10 months with a 30-month median duration of follow-up for efficacy-evaluable patients.<\/p>\n\n\n\n

In terms of safety assessment, the most frequently occurring adverse events (AE) in over 30% of patients included cytokine release syndrome (CRS; 55%), fever (pyrexia; 43%), anemia (39%), and neutropenia (31%). Among the 60 patients who underwent the recommended step-up regimen, 53% encountered cytokine release syndrome (CRS). All instances were successfully addressed with supportive measures, with a median duration of 2 days. Within this group, 40% (n=24) experienced Grade 1 CRS, 12% (n=7) had Grade 2 CRS, and 2% (n=1) had Grade 3 CRS.<\/p>\n\n\n\n

Odronextamab is currently under regulatory review for the treatment of R\/R DLBCL and R\/R FL by the U.S. Food and Drug Administration (FDA), with a target action date of March 31, 2024<\/strong>, as well as by the European Medicines Agency (EMA).<\/p>\n\n\n\n

 KOL Insights<\/strong><\/h2>\n\n\n\n

\u201cDiffuse large B-cell lymphoma has a high risk of relapse, which is why it is so critical to demonstrate continued disease control over the long term. The totality of the odronextamab data at ASH reinforces its potential as a promising treatment option for patients with this aggressive blood cancer.\u201d \u2013Expert Opinion.<\/strong><\/p>\n\n\n\n

Conclusion<\/strong><\/h2>\n\n\n\n

The key findings from the pivotal odronextamab trial demonstrated remarkable response rates, particularly within specific high-risk subgroups. Additionally, these responses exhibited durability and alignment with the outcomes observed in a Phase I trial involving patients who had previously experienced progression on CAR-T therapy.<\/p>\n\n\n\n

Refer to the Related Reports for More In-depth Insights –<\/strong><\/p>\n\n\n\n

\n
\n

Diffuse Large B-cell Lymphoma Market<\/a><\/strong><\/p>\n\n\n\n

Marginal Zone Lymphoma Market<\/a><\/strong><\/p>\n\n\n\n

Acute Lymphocytic Leukemia (ALL) Market<\/a><\/strong><\/p>\n\n\n\n

Multiple Myeloma Market<\/a><\/strong><\/p>\n\n\n\n

Chronic Lymphocytic Leukemia Market<\/a><\/strong><\/p>\n<\/div>\n\n\n\n

\n

Hodgkin’s lymphoma Market<\/a><\/strong><\/p>\n\n\n\n

Mantle Cell Lymphoma Market<\/a><\/strong><\/p>\n\n\n\n

Myelofibrosis Market<\/a><\/strong><\/p>\n\n\n\n

Myelodysplastic Syndrome Market<\/a><\/strong><\/p>\n\n\n\n

Follicular Lymphoma Market<\/a><\/strong><\/p>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Date of Abstract presentation 10th December 2023 Indications Diffuse Large B-cell lymphoma (DLBCL) Abstract Number 436 Abstract type Oral Odronextamab is an investigational CD20xCD3 bispecific antibody designed to bridge CD20 on cancer cells with CD3-expressing T cells to facilitate local T-cell activation and cancer-cell killing. The primary analysis of the Phase II trial presented at […]<\/p>\n","protected":false},"author":6,"featured_media":26046,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[41],"tags":[20413,20004,21525,21534,21533,841,927,18921],"industry":[17225],"therapeutic_areas":[17233,17228],"class_list":["post-26035","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-snippets","tag-abstracts","tag-american-society-of-hematology","tag-ash-2023","tag-ash-abstracts","tag-ash-annual-meeting-abstracts","tag-cancer-research","tag-cancer-treatment","tag-hematology","industry-pharmaceutical","therapeutic_areas-hematological-disorders","therapeutic_areas-oncology"],"acf":[],"yoast_head":"\nFinal Analysis of the Phase 2 ELM-2 Study in Patients with DLBCL<\/title>\n<meta name=\"description\" content=\"Key insights and final analysis of the Phase 2 ELM-2 Study of Odronextamab in Patients with R\/R Diffuse Large B-cell lymphoma (DLBCL)\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/final-analysis-of-the-phase-2-elm-2-study\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Final Analysis of the Phase 2 ELM-2 Study in Patients with DLBCL\" \/>\n<meta property=\"og:description\" content=\"Key insights and final analysis of the Phase 2 ELM-2 Study of Odronextamab in Patients with R\/R Diffuse Large B-cell lymphoma (DLBCL)\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/final-analysis-of-the-phase-2-elm-2-study\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2023-12-13T12:35:38+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-09-17T11:31:20+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/12\/13180527\/final-analysis-of-the-phase-2-elm-2-study.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"800\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Final Analysis of the Phase 2 ELM-2 Study in Patients with DLBCL","description":"Key insights and final analysis of the Phase 2 ELM-2 Study of Odronextamab in Patients with R\/R Diffuse Large B-cell lymphoma (DLBCL)","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/final-analysis-of-the-phase-2-elm-2-study","og_locale":"en_US","og_type":"article","og_title":"Final Analysis of the Phase 2 ELM-2 Study in Patients with DLBCL","og_description":"Key insights and final analysis of the Phase 2 ELM-2 Study of Odronextamab in Patients with R\/R Diffuse Large B-cell lymphoma (DLBCL)","og_url":"https:\/\/www.delveinsight.com\/blog\/final-analysis-of-the-phase-2-elm-2-study","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2023-12-13T12:35:38+00:00","article_modified_time":"2024-09-17T11:31:20+00:00","og_image":[{"width":1200,"height":800,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/12\/13180527\/final-analysis-of-the-phase-2-elm-2-study.png","type":"image\/png"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/final-analysis-of-the-phase-2-elm-2-study","url":"https:\/\/www.delveinsight.com\/blog\/final-analysis-of-the-phase-2-elm-2-study","name":"Final Analysis of the Phase 2 ELM-2 Study in Patients with DLBCL","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/final-analysis-of-the-phase-2-elm-2-study#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/final-analysis-of-the-phase-2-elm-2-study#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/12\/13180527\/final-analysis-of-the-phase-2-elm-2-study.png","datePublished":"2023-12-13T12:35:38+00:00","dateModified":"2024-09-17T11:31:20+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/0d96a31a370c143ffdb481d985d7edfd"},"description":"Key insights and final analysis of the Phase 2 ELM-2 Study of Odronextamab in Patients with R\/R Diffuse Large B-cell lymphoma (DLBCL)","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/final-analysis-of-the-phase-2-elm-2-study"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/final-analysis-of-the-phase-2-elm-2-study#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/12\/13180527\/final-analysis-of-the-phase-2-elm-2-study.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/12\/13180527\/final-analysis-of-the-phase-2-elm-2-study.png","width":1200,"height":800,"caption":"Phase 2 ELM-2 Study in Patients with DLBCL"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/0d96a31a370c143ffdb481d985d7edfd","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/f9314f22b8c5b61d496451e91f32488d2457ecb59283b7b2ad7e82d330b47aba?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/f9314f22b8c5b61d496451e91f32488d2457ecb59283b7b2ad7e82d330b47aba?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/arawat"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/12\/13180527\/final-analysis-of-the-phase-2-elm-2-study-300x200.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Snippets - A Small piece of News or Article<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Snippets - A Small piece of News or Article<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Abstracts<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">American Society of Hematology<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">ASH 2023<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">ASH Abstracts<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">ASH Annual Meeting Abstracts<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Cancer research<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Cancer Treatment<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Hematology<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Abstracts<\/span>","<span class=\"advgb-post-tax-term\">American Society of Hematology<\/span>","<span class=\"advgb-post-tax-term\">ASH 2023<\/span>","<span class=\"advgb-post-tax-term\">ASH Abstracts<\/span>","<span class=\"advgb-post-tax-term\">ASH Annual Meeting Abstracts<\/span>","<span class=\"advgb-post-tax-term\">Cancer research<\/span>","<span class=\"advgb-post-tax-term\">Cancer Treatment<\/span>","<span class=\"advgb-post-tax-term\">Hematology<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 2 years ago","modified":"Updated 2 years ago"},"absolute_dates":{"created":"Posted on Dec 13, 2023","modified":"Updated on Sep 17, 2024"},"absolute_dates_time":{"created":"Posted on Dec 13, 2023 6:05 pm","modified":"Updated on Sep 17, 2024 5:01 pm"},"featured_img_caption":"Phase 2 ELM-2 Study in Patients with DLBCL","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/26035","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=26035"}],"version-history":[{"count":1,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/26035\/revisions"}],"predecessor-version":[{"id":28009,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/26035\/revisions\/28009"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/26046"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=26035"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=26035"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=26035"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=26035"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=26035"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}